Teva GmbH, a global leader in generics and biopharmaceuticals, launched a survey of 3,000 patients with chronic diseases who regularly rely on medication. The survey addressed questions such as how the German population reacts to risks from global supply chains in the pharmaceutical sector, especially in times of pandemics.
The survey results show that chronic care patients in Germany would like to see less reliance on global supply chains to ensure drug production within Europe (73 percent of respondents were in favor). Also, for many, the location of production is of particular importance to avoid supply shortages of key medicines.
Chronic care patients from France, Germany, the Netherlands, Spain, Croatia, as well as the Czech Republic were also 60 percent in favor of the idea that expanding their own production would bring autonomy and sovereignty, as well as improve their economic situation (85 percent).
Three-quarters of respondents with chronic diseases such as asthma, cancer, diabetes, cardiovascular diseases, and depression favored reducing foreign suppliers. Furthermore, environmental sustainability in the form of short transportation distances and less traffic are also on the wish list.
Richard Daniell, as European head of Teva, agrees with chronic patients, as his company manufactures 95 percent of its generics in Europe, albeit still with the support of global companies and their supply chains.
The growing imbalance of the global value chain, he explains, should not lead to „unhealthy dependence.“ However, in order to strengthen Europe as a production location, what is needed above all are adjustments to economic and technological conditions as well as more flexibility and modernization of the regulatory systems. However, the price of the drug should not be the only consideration, and competition for the lowest price should be avoided.